Zimmer Biomet (ZBH) Projected to Post Quarterly Earnings on Thursday

Key Points

• Zimmer Biomet is expected to announce its Q2 2025 earnings results on August 7th, with analysts predicting earnings of $1.99 per share and revenue of $2.06 billion.
• The company's stock recently opened at $93.38, down 1.7%, and has a current market capitalization of $18.48 billion.
• A recent quarterly dividend of $0.24 per share will be paid to shareholders, representing a 1.03% dividend yield on an annualized basis.

Zimmer Biomet (NYSE:ZBH - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Zimmer Biomet to post earnings of $1.99 per share and revenue of $2.06 billion for the quarter. Zimmer Biomet has set its FY 2025 guidance at 7.900-8.100 EPS.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business's revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.94 earnings per share. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded down $1.65 during mid-day trading on Thursday, hitting $91.67. 1,801,567 shares of the company's stock traded hands, compared to its average volume of 1,618,814. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. Zimmer Biomet has a one year low of $89.22 and a one year high of $116.71. The firm has a 50 day moving average price of $93.21 and a 200 day moving average price of $100.48. The company has a market cap of $18.14 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 2.18 and a beta of 0.71.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Wall Street Analyst Weigh In

ZBH has been the topic of several research analyst reports. Robert W. Baird lowered their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company dropped their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Roth Capital raised Zimmer Biomet from a "neutral" rating to a "buy" rating and set a $135.00 price objective on the stock in a research note on Tuesday, July 15th. Finally, Morgan Stanley decreased their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $111.39.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.39% of the company's stock.

Institutional Trading of Zimmer Biomet

A hedge fund recently bought a new stake in Zimmer Biomet stock. Brighton Jones LLC acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,936 shares of the medical equipment provider's stock, valued at approximately $204,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.